The observations made in this study cannot directly be translated to other cancer types, since the behavior of RAS mutation variants is dependent on the location and cell type of the tumor.11 For example, the large number of samples analyzed and reported in cBioPortal21 show that KRAS A146 mutations are rarely reported in other cancer types except for CRC.21-23 Although the prevalence of A146 mutations among KRAS mutation carriers in CRC is approximately 8%, similar to our observation in this study, it is only 0%-0.5% in both lung24-26 and pancreas cancer.27,28. This evidence concerns the gene KRAS and pancreatic neoplasm.